CAPR, BBIO, RPRX and COGT set up a late-November FDA cluster with rare-disease approval stakes
Capricor faces a Nov. 22 FDA decision on deramiocel for Duchenne muscular dystrophy, with debate centered on how regulators weigh its cardiac data and rare-disease context. BridgeBio and Royalty Pharma both have Nov. 27 PDUFA dates, while Cogent follows on Nov. 30, creating a compact run of late-November FDA catalysts across muscle disease and other specialty indications.
Read the full brief →